HTL Biotechnology Inaugurates €15 Million HTL8 Polynucleotide Plant in Javené

HTL Biotechnology inaugurated HTL8, a €15 million production unit for pharmaceutical-grade polynucleotides, at its Javené site in Ille-et-Vilaine on November 12, 2026. The French biotech announced the inauguration through PR Newswire on November 13. HTL Biotechnology is a French company founded in 1992 that develops and produces pharmaceutical-grade biopolymers, including hyaluronic acid and polynucleotides, for healthcare customers.

Inside the HTL8 Polynucleotide Unit

HTL8 is dedicated to purifying pharmaceutical-grade polynucleotides, biopolymers made of nucleotide chains that are used for their regenerative properties, including tissue repair, hydration and improved skin quality. HTL Biotechnology makes its polynucleotides from DNA extracted from wild Alaskan salmon milt, a co-product of the salmon industry that is recovered and used as a pharmaceutical raw material.

The company said the unit combines advanced equipment and automation with tighter control of critical process parameters and rigorous quality and safety requirements. HTL8 is intended to support new applications in regenerative medicine, ophthalmology and dermatology, including wound healing, and to serve growing demand, particularly in Asian markets.

"This new unit is fully in line with the €100 million investment plan launched in 2022," said François Fournier, CEO of HTL Biotechnology. Fournier said the company monitors its markets and anticipates their developments by placing customer expectations at the heart of its strategy.

HTL Biotechnology's Investment Record

HTL Biotechnology's 2022-2026 investment plan of €100 million has contributed to its international development and the diversification of its portfolio, according to akta.pro company records. In May 2024 the company acquired Modern Meadow's human recombinant collagen platform, including recombinant proteins and an expert team, adding human recombinant collagen Type III to its biopolymer portfolio, the same records show. That month it also launched human recombinant collagen Type III products for cosmetic and medical markets.

What Comes Next for HTL8

HTL Biotechnology is building a neuromodulator production unit in the United States through HTL BMI in Massachusetts, and it has subsidiaries in Asia. The company employs nearly 300 people worldwide.